MedPath

The NOICH Study.

Completed
Conditions
Fetal or Neonatal Alloimmune Thrombocytopenia
Registration Number
NL-OMON21014
Lead Sponsor
Sanquin Bloodbank Amsterdam provides the trial medication
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
212
Inclusion Criteria

1. Pregnant women with a subsequent pregnancy after prior pregnancy complicated by HPA alloimmunization who have given birth to a child with a platelet count < 150 x 10 9/l in the first week of life;

2. HPA alloimmunization must have been confirmed by the presence of maternal anti-HPA antibodies and the offending HPA antigen in the fetus or homozygous partner;

Exclusion Criteria

1. Pregnant women with autoimmune thrombocytopenia;

2. Twins or multiple pregnancies;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
umber of neonates with intracranial hemorrhage.
Secondary Outcome Measures
NameTimeMethod
Cord blood platelet count at birth.<br /><br>Other variables studied will be the levels of maternal and neonatal anti-HPA antibodies and IgG, the occurrence of other bleedings in the neonate as well as the necessity and type of neonatal treatment.
© Copyright 2025. All Rights Reserved by MedPath